Drug site selection ｜ Medical and Health Industrial Park reported for investigation in June!
Data of drug site selection in June
Item 1: xin3 in third-party medical examinationProject Description: This enterprise is a high-tech enterprise engaged in biomedicine and disease detection. Committed to the nucleic acid and biochemical detection of diseases, as well as the research and development, production and sales of various products in the biomedical direction.
Highlights of the project: The industrial chain that has become "product+sales+inspection" belongs to the field: Precision medical investment scale: 10 million revenue status: regulated enterprise intention area: Yangtze River Delta region.
Project 2: High-end preparation production project of generic drugsProject Description: The company was established in January 2011, focusing on the development of high-end preparation technology and the industrialization of related technologies, and providing technical services of consulting, commissioned development, transfer, authorization and conformity evaluation. The company has five drug research and development technology platforms, including generic drug consistency evaluation preparation platform, targeted nano-preparation technology platform, long-acting injection microsphere technology platform, oral sustained-release preparation platform and polyethylene glycol preparation technology platform.
Highlights of the project: the company has established more than 30 projects, including one approved by the US FDA for listing; One supplementary application has passed the consistency evaluation, and two applications are in CDE review; Nine BE tests have passed the consistency evaluation and four BE pre-tests have been completed. Industry: High-end generic drug investment scale: 400-500 million revenue status: temporarily undisclosed intention area: Pearl River Delta.
Project 3: Research project of new marine oligosaccharide drugs.Project Description: The company is mainly committed to the brand-new drug research of antineoplastic drugs, antiepileptic drugs and marine drugs. The company’s main management personnel have rich company management experience, profound technical background and rich experience in new drug research and development.
Highlights of the project: The R&D team includes pharmacology, preparations, analysis and other professionals. At present, there are 1 professor, 4 doctors and several masters. Industry: New drug R&D investment scale: tens of millions of revenue status: valuation of 10 billion after listing Intention area: Sichuan and Chongqing, Shenzhen
03 Introduction of certified V Park
In June, 12 new certification parks were completed in the drug site selection, with a total of 195 certification parks, including 65 national parks. There are 116 platform V parks, and the typical V parks added this month are:
[Tianjin Economic and Technological Development Zone]
Industrial clusters:Automobile, medicine, equipment manufacturing, biological products, chemicals, traditional Chinese medicine, natural medicine, medical equipment.
Tianjin Economic and Technological Development Zone, founded on December 6, 1984, is located 40 kilometers east of Tianjin urban area. It is an important part of Tianjin Binhai New Area and a part of the national comprehensive reform pilot zone. It is one of the first national economic and technological development zones in China.
[Dadi (International) Life Science Park]
Industrial clusters:Biomedicine, medical equipment, biotechnology.
Dadi (International) Life Science Park is located in the core area of Liangjiang Water and Soil New City in Chongqing, with a total area of about 400 mu, a planned area of 600,000 square meters and a total investment of about 2 billion yuan. This park is the expansion area of Dadi Enterprise Park, a part of Chongqing Liangjiang New Area’s scientific and technological innovation base built by the Ministry of Science and Technology, the core bearing place of Chongqing Liangjiang New Area’s Overseas Students Pioneer Park Incubation Center awarded by the Ministry of Human Resources and Social Security, and a professional biomedical park supported by Chongqing Municipal Government and Liangjiang New Area.
At present, Dadi Enterprise Park has attracted more than 110 innovative pharmaceutical enterprises, and has initially formed a biomedical industry cluster.
[Beidaihe Life and Health Industry Innovation Demonstration Zone]
Industrial clusters:Health service industry, health manufacturing industry, health service and medical service.
Beidaihe Life and Health Industry Innovation Demonstration Zone has a planned area of 520 square kilometers, including Beidaihe District, the area south of Beidaihe and the airport area of Beidaihe International Airport.
[Dabaihui Life and Health Industrial Park]
Industrial clusters:IVD industrial cluster, medical device park, genetic testing.
Dabaihui Life and Health Industrial Park is located in the core administrative business district of Yantian District. It focuses on industries with high development potential, high technology content and high growth, such as biotechnology, medicine and medical equipment, medical artificial intelligence, etc., and builds a whole industry chain that integrates specialized industrial space, precise industrial operation platform, full-stage financial service system, competitive industrial support and talent policy, and strives to build a life with the largest scale, the best policies, the most mature supporting facilities and the highest degree of specialization in Shenzhen.
04 Introduction of investment location of biomedical enterprises in June
[Haier Bio and Qingdao High-tech Zone to Build Haier Biosafety Science and Technology Industrial Park]
On June 3rd, Qingdao High-tech Zone signed a contract with Haier Biomedical Co., Ltd. to land the project of "Haier Biosafety Science and Technology Industrial Park", with a total investment of 500 million yuan, which is mainly to build a biological cultivation R&D and manufacturing center, an IVD R&D and manufacturing center, an automated R&D and manufacturing center, a biosafety incubator, a common R&D experimental center, a cold chain transshipment R&D and a bio-centrifugal preparation and manufacturing center, etc. After the project starts, it is expected to be completed and put into production within two years.
Haier Biomedical Co., Ltd. and Qingdao Haier Biomedical Co., Ltd. started from the research and development, production and sales of biomedical cryogenic storage equipment, and transformed into a comprehensive biotechnology solution service provider based on the Internet of Things. Facing the global market, Haier Biomedical mainly provides low-temperature storage comprehensive solutions for biological sample bank, blood safety, vaccine safety, drug and reagent safety and other scenarios.
[Hongri Pharmaceutical invested 750 million yuan to build an automated production base project]
On June 7th, Shandong Hongri Kangrentang Pharmaceutical Co., Ltd. held a groundbreaking ceremony in Shanghe Economic Development Zone, Jinan. With an investment of 750 million yuan and an estimated annual output value of 10,000 tons, the project will be the eighth automatic production base of Hongri Pharmaceutical, which will further improve Jinan’s biomedical industry chain and promote the chain-type large-scale cluster development of Jinan’s traditional Chinese medicine industry, which is of great significance to Jinan’s efforts to build an ecological system of biomedical and health industries with world influence.
Founded in 1996, Hongri Pharmaceutical Co., Ltd. is a listed pharmaceutical enterprise with a market value of over 10 billion yuan. It is a high-tech pharmaceutical and health industrial cluster integrating investment, financing, production, R&D and sales, spanning many fields such as finished drugs, traditional Chinese medicine granules, raw materials, medical devices, medical and health services, and medical equipment smart supply chain.
[Huaheng Bio’s wholly-owned subsidiary invested 250 million yuan to build a three-chain amino acid and its derivatives project]
On June 10th, Huaheng Bio plans to invest 250 million yuan to build a three-chain amino acid and its derivatives project with an annual output of 16,000 tons in shanba Industrial Park, Hangjinhouqi, Bayannaoer, with Bayannaoer Huaheng Biotechnology Co., Ltd. as the main body. The project covers an area of 20 mu and the investment amount does not exceed 250 million yuan. The source of funds for this investment project is mainly self-raised, and the estimated construction period is 18 months.
[Chengyi Pharmaceutical plans to invest 670 million yuan to build a marine biomedical manufacturing project]
On June 16th, Chengyi Pharmaceutical Company plans to invest about 670 million yuan to start the second phase project of building a healthy industrial park, tentatively named as "Marine Biomedical Manufacturing Project", aiming at developing marine biomedicine and traditional Chinese medicine. It is planned to produce 1000 tons of super fish oil EPA and traditional Chinese medicine projects every year. The main products include fish oil, Chinese medicine extraction (Megan) and Chinese medicine pieces.
Chengyi Pharmaceutical specializes in the research, development, production and sales of preparations and raw materials. The main products include glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, etc., and the therapeutic range of products involves arthritis and diuresis. Marine biomedical manufacturing projects take marine biomedicine and traditional Chinese medicine as the main development direction of the company. The implementation of the project will transform and upgrade Dongtou as a national marine economic development demonstration zone, which is also conducive to the long-term development of the company.
Note: The above contents are organized through public channels on the Internet, and the copyright belongs to the original text. Authors: Chi Fangbing, Zhao Fei, Yan Huali, Zhong Lingyu.